Innate Pharma S.A. (IPHA)
NASDAQ: IPHA
· Real-Time Price · USD
2.10
0.08 (3.96%)
At close: Sep 04, 2025, 3:59 PM
2.05
-2.19%
After-hours: Sep 04, 2025, 04:00 PM EDT
3.96% (1D)
| Bid | 1.96 |
| Market Cap | 170.05M |
| Revenue (ttm) | 12.62M |
| Net Income (ttm) | -49.47M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -2.95 |
| Forward PE | 22.44 |
| Analyst | Buy |
| Ask | 2.2 |
| Volume | 11,741 |
| Avg. Volume (20D) | 10,537 |
| Open | 2.10 |
| Previous Close | 2.02 |
| Day's Range | 2.02 - 2.16 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | 0.93 |
About IPHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IPHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IPHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+20.62%
Innate Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
9 months ago
+29.25%
Innate Pharma shares are trading higher after the company announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.
